Studies on the biological effects of ozone: 5. Evaluation of immunological parameters and tolerability in normal volunteers receiving ambulatory autohaemotherapy
- 1 June 1993
- journal article
- Published by Springer Nature in Biotherapy
- Vol. 7 (2) , 83-90
- https://doi.org/10.1007/bf01877731
Abstract
Autohaemotherapy, after a bland treatmentex vivo of blood with ozone, is a fairly unknown medical procedure claimed to have therapeutic value in viral diseases and neoplasms. Having already shown that ozone acts as a mild inducer of cytokines, we have undertaken an investigation in normal rabbits and in normal volunteers aiming to evaluate eventual changes of some cytokine levels in plasma as well as of immunological parameters such as the Mx protein, neopterin,β2-microglobulin and of some acute-phase proteins after single or repeated autohaemotherapy. We have also evaluated the potential development of side-effects. This study is the first one to show that autohaemotherapy can activate an immunological marker in normal subjects without procuring any toxic effects.Keywords
This publication has 16 references indexed in Scilit:
- Human Renal Carcinoma Line Transfected With Interleukin-2 and/or Interferon Gene(s): Implications for Live Cancer VaccinesJNCI Journal of the National Cancer Institute, 1993
- Double-Blind Randomized Phase I Study on the Clinical Tolerance and Biological Effects of Natural and Recombinant Interferon-βJournal of Interferon Research, 1992
- Ozonization of blood for the therapy of viral diseases and immunodeficiencies. A hypothesisMedical Hypotheses, 1992
- A Whole Blood Immunoassay for the Interferon-Inducible Human Mx ProteinJournal of Interferon Research, 1992
- InterleukinsClinical Pharmacokinetics, 1991
- Interferon induction in rabbits after intraduodenal administration of a phosphorylated glucomannan-protein fraction of the cell wall of Candida albicansImmunology Letters, 1991
- Metabolism of protein anticancer agentsPharmacology & Therapeutics, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Generation of a soluble IFN-γ inducer by oxidation of galactose residues on macrophagesCellular Immunology, 1985